FDA advisory panel endorses booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine

WASHINGTON (AP) — FDA advisory panel endorses booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine.

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.903 of 5 stars
$148.57-0.5%3.20%9.26Hold$175.86
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: